Stevenage Bioscience Catalyst (SBC) has launched an accelerator program for biotech start-ups focusing on data-enabled drug discovery, genomics and advanced therapies: aiming to give such companies the skills they need to get potential new drugs and therapies...
The Oxford-GSK Institute of Molecular and Computational Medicine has been created via a five-year collaboration between GlaxoSmithKline and the University of Oxford.
UK catalyst organization, CPI, has announced the launch of a project that aims to revolutionize the manufacture of oligonucleotides, through a collaboration involving, among others, AstraZeneca, Exactmer, and Novartis.
GSK’s biopharmaceutical manufacturing facility will be focused on the company’s pipeline of biologic medicines, including gene therapies, and vaccines.
Four pharma companies are providing half of the investment required for ‘world’s largest genetics project’, in return for access to the genomic data generated.
New data on the genetic biomarkers impacting the development of cancer treatments has been released creating the largest publicly accessible dataset of its kind.
GSK signs partnership deal with the University of California to advance genomic research, which sees the creation of a lab and funding for five years of research.
